Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR BCMA-CD70 CAR-T Therapy for High-risk Plasma Cell Neoplasms
NCT07416682Phase 1Recruiting
- Sponsor
- Academy of Military Medical Sciences
- Start
- Apr 2026
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA-CD70 CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences) in plasma cell neoplasm, sponsored by Academy of Military Medical Sciences. Primary endpoints: Incidence of treatment-related adverse events at 3 years and Maximal Tolerable Dose at 28 days. Started Apr 2026; status: recruiting.
02
Drugs
BCMA-CD70 CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences)
03
Conditions
plasma cell neoplasm
Beyond the preview
Go deeper on NCT07416682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416682.